Reynoso Jamie L. sold $9K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 1,921 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.56 on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Sep 18, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 11:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosed sale is small relative to the CEO's total holdings and is part of a pre‑arranged trading plan, suggesting limited new insight for traders.

02

Market read

Routine insider transaction with negligible market impact.

03

What to watch

The sale is pre‑arranged under a 10b5‑1 plan, reducing the likelihood of new information.

Relevance 2/10Novelty 3/10Timing: filing date 2026-09-18

Background

Clover Health Investments (CLOV) is a publicly traded health‑tech company. Form 4 filings disclose insider transactions.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

CEO Reynoso Jamie L. sold 1,921 shares of Clover Health for $8,760 via a 10b5-1 plan.

Expected impact

No material price movement expected; possible short‑term dip of <1% if market reacts.

Evidence & confidence

The sale represents only 0.07% of total shares held and is pre‑arranged, limiting informational value.

Market effects

No sector-wide impact; insider sales are routine in health‑tech.

Limited to US market, no broader regional effect.

Minimal global relevance.

Counterpoint

Some investors may view any insider sell as a red flag and short the stock.

Key entities

  • Reynoso Jamie L.

    CEO of Clover Health Investments

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.